Pharma Foods International Co., Ltd. (JP:2929)
:2929
Want to see JP:2929 full AI Analyst Report?
2929 Stock Chart & Stats
¥679.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥679.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥513.00 - ¥1,064.00
Previous CloseN/A
Volume159.60K
Average Volume (3M)110.46K
Market Cap
¥15.73B
Enterprise Value¥23.93B
Total Cash (Recent Filing)¥8.77B
Total Debt (Recent Filing)¥17.21B
Price to Earnings (P/E)36.9
Beta0.81
Next Earnings
Sep 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.65%
Share Statistics
EPS (TTM)14.72
Shares Outstanding29,079,000
10 Day Avg. Volume122,950
30 Day Avg. Volume110,460
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)2.21
Price to Sales (P/S)0.39
P/FCF Ratio-12.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth indicates continued product demand and market traction for wellness and functional-ingredient offerings. Over 2–6 months this supports scale benefits, predictable top-line for planning, and the ability to fund product development and distribution expansion without relying solely on financing.
Very High Gross Profit MarginAn >80% gross margin reflects strong unit economics and likely proprietary ingredients/formulations, giving pricing power and a structural margin buffer. This durable advantage helps absorb SG&A or marketing investment, supporting margin recovery and long-term ability to invest in R&D and channel development.
Reduced LeverageMarked reduction in leverage materially improves financial flexibility and lowers interest burden, strengthening ability to fund operations or capex from internal resources. Over months this reduces refinancing risk, supports dividend continuity, and provides capacity to pursue strategic investments or partnerships.
Bears Say
Negative Operating And Free Cash FlowNegative operating and free cash flow signal the business is not converting revenue into sustainable cash, forcing reliance on financing or asset sales to fund operations and dividends. This weak cash generation is a structural risk to reinvestment, product launches, and balance sheet resilience over the coming months.
Sharp Net Margin DeteriorationA collapse in net margin suggests rising operating costs or pressure on pricing that erodes the benefit of high gross margins. Persistently thin net profitability reduces retained earnings, constrains reinvestment, and makes it harder to sustain dividends or fund strategic initiatives without improving operational efficiency.
Declining Returns And Weak Cash ConversionFalling ROE alongside a high free-cash-flow-to-net-income ratio indicates profits are not translating into cash returns for shareholders. This structural efficiency gap impairs capital allocation effectiveness and heightens vulnerability to spending shocks, limiting long-term growth and shareholder return prospects.
Pharma Foods International Co., Ltd. News
2929 FAQ
What was Pharma Foods International Co., Ltd.’s price range in the past 12 months?
Pharma Foods International Co., Ltd. lowest stock price was ¥513.00 and its highest was ¥1064.00 in the past 12 months.
What is Pharma Foods International Co., Ltd.’s market cap?
Pharma Foods International Co., Ltd.’s market cap is ¥15.73B.
When is Pharma Foods International Co., Ltd.’s upcoming earnings report date?
Pharma Foods International Co., Ltd.’s upcoming earnings report date is Sep 14, 2026 which is in 80 days.
How were Pharma Foods International Co., Ltd.’s earnings last quarter?
Pharma Foods International Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥26.42 earnings per share for the quarter, beating the consensus estimate of N/A by ¥26.42.
Is Pharma Foods International Co., Ltd. overvalued?
According to Wall Street analysts Pharma Foods International Co., Ltd.’s price is currently Overvalued.
Does Pharma Foods International Co., Ltd. pay dividends?
Pharma Foods International Co., Ltd. pays a Semiannually dividend of ¥12.402 which represents an annual dividend yield of 3.65%. See more information on Pharma Foods International Co., Ltd. dividends here
What is Pharma Foods International Co., Ltd.’s EPS estimate?
Pharma Foods International Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharma Foods International Co., Ltd. have?
Pharma Foods International Co., Ltd. has 29,079,000 shares outstanding.
What happened to Pharma Foods International Co., Ltd.’s price movement after its last earnings report?
Pharma Foods International Co., Ltd. reported an EPS of ¥26.42 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -13.376%.
Which hedge fund is a major shareholder of Pharma Foods International Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Foods International Co., Ltd.
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a specific egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg. Additionally, the company offers iHA, a compound recognized for stimulating the body's hyaluronic acid production. Furthermore, Pharma Foods International Co., Ltd. has entered into a licensing arrangement with Mitsubishi Tanabe Pharma Corporation for a novel therapeutic antibody designed to combat autoimmune conditions. The firm was founded in 1997 and maintains its corporate headquarters in Kyoto, Japan.
Technical Analysis
―
Tsumura & Co
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Options Prices
Currently, No data available
---